These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36874318)

  • 21. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary prevention implantable cardioverter defibrillator in cardiac resynchronization therapy recipients with advanced chronic kidney disease.
    Goldenberg I; Kutyifa V; Zareba W; Huang DT; Rosero SZ; Younis A; Schuger C; Gao A; McNitt S; Polonsky B; Steinberg JS; Goldenberg I; Aktas MK
    Front Cardiovasc Med; 2023; 10():1237118. PubMed ID: 37680559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators.
    Ermis C; Seutter R; Zhu AX; Benditt LC; VanHeel L; Sakaguchi S; Lurie KG; Lu F; Benditt DG
    J Am Coll Cardiol; 2005 Dec; 46(12):2258-63. PubMed ID: 16360055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response of right ventricular size to treatment with cardiac resynchronization therapy and the risk of ventricular tachyarrhythmias in MADIT-CRT.
    Doyle CL; Huang DT; Moss AJ; Solomon SD; Campbell P; McNitt S; Polonsky S; Barsheshet A; Aktas M; Tompkins C; Zareba W; Goldenberg I
    Heart Rhythm; 2013 Oct; 10(10):1471-7. PubMed ID: 23872690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction.
    Liu LW; Wu PC; Chiu MY; Tu PF; Fang CC
    Acta Cardiol Sin; 2020 Mar; 36(2):125-132. PubMed ID: 32201463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non-responders: a retrospective analysis.
    Chun KH; Oh J; Yu HT; Lee CJ; Kim TH; Uhm JS; Pak HN; Lee MH; Joung B; Kang SM
    ESC Heart Fail; 2020 Dec; 7(6):4404-4407. PubMed ID: 32918402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Eligibility for Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry.
    Oh J; Lee CJ; Park JJ; Lee SE; Kim MS; Cho HJ; Choi JO; Lee HY; Hwang KK; Kim KH; Yoo BS; Choi DJ; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Kang SM
    Int J Heart Fail; 2019 Oct; 1(1):57-68. PubMed ID: 36262737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.
    Young JB; Abraham WT; Smith AL; Leon AR; Lieberman R; Wilkoff B; Canby RC; Schroeder JS; Liem LB; Hall S; Wheelan K;
    JAMA; 2003 May; 289(20):2685-94. PubMed ID: 12771115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
    Monzo L; Gaudio C; Cicogna F; Tota C; Petronilli V; Mennuni S; De Ruvo E; Calò L
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5690-5700. PubMed ID: 34604961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appropriate implantable cardioverter-defibrillator interventions in cardiac resynchronization therapy-defibrillator (CRT-D) patients undergoing device replacement: time to downgrade from CRT-D to CRT-pacemaker? Insights from real-world clinical practice in the DECODE CRT-D analysis.
    Narducci ML; Biffi M; Ammendola E; Vado A; Campana A; Potenza DR; Iori M; Zanon F; Zacà V; Zoni Berisso M; Bertini M; Lissoni F; Bandini A; Malacrida M; Crea F
    Europace; 2018 Sep; 20(9):1475-1483. PubMed ID: 29186401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.
    Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W
    Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.
    Guo Y; Ren M; Wang T; Wang Y; Pu T; Li X; Yu L; Wang L; Liu P; Tang L
    Front Cardiovasc Med; 2022; 9():955780. PubMed ID: 36440034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Failure Sections of the Polish Cardiac Society.
    Grabowski M; Ozierański K; Balsam P; Dąbrowski R; Farkowski MM; Gackowski A; Jędrzejczyk-Patej E; Kalarus Z; Leszek P; Nessler J; Sterliński M; Opolski G; Przybylski A
    Kardiol Pol; 2019 Oct; 77(10):987-993. PubMed ID: 31527563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between New York Heart Association class change and ventricular tachyarrhythmia occurrence in patients treated with cardiac resynchronization plus defibrillator.
    Lepillier A; Piot O; Gerritse B; Copie X; Lavergne T; Paziaud O; Lascault G; Waintraub X; Otmani A; Le Heuzey JY
    Europace; 2009 Jan; 11(1):80-5. PubMed ID: 18952828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved Beyond Guidelines for a Defibrillator in MADIT-CRT.
    Sherazi S; Shah F; Kutyifa V; McNitt S; Aktas MK; Polonsky B; Zareba W; Goldenberg I
    JACC Clin Electrophysiol; 2019 Oct; 5(10):1172-1181. PubMed ID: 31648742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events.
    Szepietowska B; Polonsky B; Sherazi S; Biton Y; Kutyifa V; McNitt S; Aktas M; Moss AJ; Zareba W
    Cardiovasc Diabetol; 2016 Jul; 15():93. PubMed ID: 27388610
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.